Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics

Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has seen a surge in the development of diagnostic assays. However, the performance of antigen point-of-care tests (Ag-POCTs) on samples with low viral load has not been evaluated. Aim: To evaluate the accuracy...

Full description

Saved in:
Bibliographic Details
Main Author: Ivy Rukasha
Format: Article
Language:English
Published: AOSIS 2025-03-01
Series:African Journal of Primary Health Care & Family Medicine
Subjects:
Online Access:https://phcfm.org/index.php/phcfm/article/view/4671
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850275013851086848
author Ivy Rukasha
author_facet Ivy Rukasha
author_sort Ivy Rukasha
collection DOAJ
description Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has seen a surge in the development of diagnostic assays. However, the performance of antigen point-of-care tests (Ag-POCTs) on samples with low viral load has not been evaluated. Aim: To evaluate the accuracy of three World Health Organization (WHO) certified Ag-POCTs in comparison to the reverse transcription polymerase chain reaction (RT-PCR) technique. Setting: The study was conducted at Pietersburg Hospital Limpopo, South Africa between March 2020 and April 2023. Methods: A total of 371 SARS-CoV-2 nasopharyngeal samples from the National Health Laboratory Service were tested using Ag-POCTs from Abbott Panbio, Roche RDT and SD Biosensor, following manufacturer instructions. All samples had RT-PCR results with Ct values between 13 and 45. Reverse transcription polymerase chain reaction results were compared and correlated with Ag-POCT results. Results: Of the 371 samples, the SD Biosensor Standard Q test kit detected the most positive isolates 166 (44.7%), followed by the Abbott Panbio. A total of 153 (41.2%) positives, while the Roche SD detected 134 (36.1%) samples. High viral load (Ct 25) sensitivity and specificity exceeded 77%, while intermediate (Ct 25–35) and low viral load (Ct 35) sensitivity and sensitivity dropped to 32% and 7%, respectively. Conclusion: The performance rapid antigen tests was low on samples with low viral load with results markedly different from the manufacturer’s reported performance. Contribution: Rapid antigen tests should not be used alone for diagnosis, especially in samples with low viral load.
format Article
id doaj-art-71cecd8da60d44ce97b9a14d5e65792e
institution OA Journals
issn 2071-2928
2071-2936
language English
publishDate 2025-03-01
publisher AOSIS
record_format Article
series African Journal of Primary Health Care & Family Medicine
spelling doaj-art-71cecd8da60d44ce97b9a14d5e65792e2025-08-20T01:50:57ZengAOSISAfrican Journal of Primary Health Care & Family Medicine2071-29282071-29362025-03-01171e1e710.4102/phcfm.v17i1.46711229Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemicsIvy Rukasha0Department of Pathology, Faculty of Health Sciences, University of Limpopo, Polokwane, South Africa; and Department of Medical Microbiology, National Health Laboratory Services, PolokwaneBackground: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has seen a surge in the development of diagnostic assays. However, the performance of antigen point-of-care tests (Ag-POCTs) on samples with low viral load has not been evaluated. Aim: To evaluate the accuracy of three World Health Organization (WHO) certified Ag-POCTs in comparison to the reverse transcription polymerase chain reaction (RT-PCR) technique. Setting: The study was conducted at Pietersburg Hospital Limpopo, South Africa between March 2020 and April 2023. Methods: A total of 371 SARS-CoV-2 nasopharyngeal samples from the National Health Laboratory Service were tested using Ag-POCTs from Abbott Panbio, Roche RDT and SD Biosensor, following manufacturer instructions. All samples had RT-PCR results with Ct values between 13 and 45. Reverse transcription polymerase chain reaction results were compared and correlated with Ag-POCT results. Results: Of the 371 samples, the SD Biosensor Standard Q test kit detected the most positive isolates 166 (44.7%), followed by the Abbott Panbio. A total of 153 (41.2%) positives, while the Roche SD detected 134 (36.1%) samples. High viral load (Ct 25) sensitivity and specificity exceeded 77%, while intermediate (Ct 25–35) and low viral load (Ct 35) sensitivity and sensitivity dropped to 32% and 7%, respectively. Conclusion: The performance rapid antigen tests was low on samples with low viral load with results markedly different from the manufacturer’s reported performance. Contribution: Rapid antigen tests should not be used alone for diagnosis, especially in samples with low viral load.https://phcfm.org/index.php/phcfm/article/view/4671poor performancepoint-of-care testscovid-19low viral loadantigen testsdiagnostic accuracysars cov-2.
spellingShingle Ivy Rukasha
Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics
African Journal of Primary Health Care & Family Medicine
poor performance
point-of-care tests
covid-19
low viral load
antigen tests
diagnostic accuracy
sars cov-2.
title Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics
title_full Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics
title_fullStr Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics
title_full_unstemmed Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics
title_short Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics
title_sort limitations of point of care testing for low sars cov 2 loads insights for future pandemics
topic poor performance
point-of-care tests
covid-19
low viral load
antigen tests
diagnostic accuracy
sars cov-2.
url https://phcfm.org/index.php/phcfm/article/view/4671
work_keys_str_mv AT ivyrukasha limitationsofpointofcaretestingforlowsarscov2loadsinsightsforfuturepandemics